Kiniksa posts Q1 beat thanks to Regeneron drug (KNSA:NASDAQ)

Regeneron (REGN) reported Q2 2026 revenue of $4.29B vs $3.82B Street estimate, with adjusted EPS $14.29 vs $10.21. EBIT was $1.65B vs $1.19B estimate, and EBIT margin rose to 38.53%. CFO said Regeneron fully repaid a Sanofi development balance, and collaboration revenue should step up in Q3. Dupixent sales grew 38% constant currency; EYLEA HD first outsold EYLEA in the U.S.

Regeneron reported Q2 2026 results with global Dupixent sales of about $6B, up 38% year over year versus an analyst estimate of $5.34B. Regeneron also fully repaid Sanofi’s remaining ~$278M development balance, ending a 20% profit diversion. Q2 revenue rose 17% to ~$4.29B and non-GAAP EPS was $14.29.

Thursday, July 30, 2026 at 8:30 a.m.

US stock index futures rose in premarket after a prior selloff tied to Fed-related concerns. Microsoft shares jumped about 9% after cloud growth accelerated, while Meta fell about 8% after revenue guidance disappointed and free cash flow was weak. Bond selling slowed and 30-year yields hit a two-decade high near 5.22%. Several other earnings moves were reported, including MO, CVNA, CMG, and QCOM.

Regeneron (NASDAQ:REGN) reported Q2 CY2026 results with revenue up 16.7% year on year to $4.29 billion, exceeding Wall Street estimates by 12.4%, according to the company. Non-GAAP adjusted EPS was $14.29, up from $12.89, and above consensus by 40.1%. The stock rose 4.7% to $727.79 after the release.

Regeneron Pharmaceuticals (REGN) shares rose about 3% in pre-open after the company reported Q2 2026 results above forecasts. Adjusted EPS was $14.29 versus ~$10.58 expected, and revenue was $4.29B versus ~$3.81B. Dupixent, Eylea HD, and Libtayo sales hit record highs, and Sanofi Development Balance was repaid; cemdisiran submissions were accepted by FDA and EMA.